Piotr Swat | Light Rocket | Getty Images
him and her The company announced Saturday that it would pull its copy weight loss drug from the market after it sparked controversy and threatened a lawsuit earlier this week.
“Since launching combination semaglutide tablets on our platform, we have had constructive conversations with stakeholders across the industry,” the telemedicine provider posted on social media. “As a result, we have decided to discontinue providing access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable and personalized care.”
Hims & Hers has previously said it plans to develop a cheaper copycat version of the drug giant. novo nordisk Wegovy Weight Loss Pills. The treatment, which features Wegovy’s active ingredient semaglutide, was scheduled to be available for just $49 for the first month. Novo’s pills sell for about $100 more.
Novo on Thursday threatened legal action against what Hims called “illegal bulk compounding,” adding that it planned to take legal and regulatory action.
“This is another example of Hims & Hers’ historic actions to deceive the American public with counterfeit GLP-1 products, and the FDA has previously warned Hims & Hers about deceptive advertising of counterfeit GLP-1 products,” Novo said in a statement at the time.
On Friday, the U.S. Food and Drug Administration agreed, announcing that it plans to take legal action against Hims & Hers over the pill, including restricting access to its ingredients and reporting it to the Department of Justice.
In response, Hims said on Saturday that it had “always operated with a focus on the safety and best interests of our consumers and in compliance with applicable law.”
The move comes as the company plans to run an ad during Super Bowl 60 on Sunday. In this ad, rapper Common expresses the message that “wealth inequality in America has turned into health inequality.”
Hims previously said it expected the ad to “ruffle feathers”.
